FDA Approves Regeneron Pharmaceuticals, Inc. (REGN)’s Linvoseltamab for Multiple Myeloma

We recently published 11 Best Cancer Stocks to Buy Right Now. Regeneron Pharmaceuticals, Inc. is placed second among the best cancer stocks.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biopharmaceutical company recognized for advancing cancer treatment through innovative immunotherapies and biologics. Its flagship PD-1 inhibitor, Libtayo, is the standard of care for advanced cutaneous squamous cell carcinoma (CSCC) and is being explored in other cancers such as melanoma and multiple myeloma.

At the 2025 ASCO Annual Meeting, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is presenting 18 studies across hard-to-treat cancers, underscoring the depth of its oncology pipeline. Key highlights include the C-POST Phase 3 trial, showing Libtayo significantly improved disease-free survival in high-risk CSCC after surgery.

Another major focus is linvoseltamab, a BCMAxCD3 bispecific antibody for relapsed or refractory multiple myeloma. The drug recently gained FDA approval (Lynozyfic) and is being tested in combination regimens with proteasome inhibitors, potentially broadening its clinical use. Additionally, vidutolimod, a toll-like receptor 9 agonist, is being evaluated with PD-1 inhibitors in melanoma, with Phase 2 results to be shared.

A scientist in a lab researching the biology of a cancer cell.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s oncology strategy emphasizes immuno-oncology combinations, including checkpoint inhibitors and bispecific antibodies, to address both solid tumors and hematological cancers. With Libtayo demonstrating strong results in CSCC and linvoseltamab offering a new option for multiple myeloma, the company is expanding its role in areas with significant unmet need.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.